Bevacizumab in combination with capecitabine and irinotecan (XELIRi) in treatment of metastatic colorectal cancer;Bevacizumab v kombinaci s kapecitabinem a irinotekanem (XELIRI) v léčbě metastatického kolorektálního karcinomu

Klinicka Onkologie

Volumn 22, Issue 2, 2009, Pages 73-76

  Kocáková, Ilona ^a   Kocak I ^a   Svoboda, M ^a   Nemecek R ^a   Rehak Z ^a   Standara, M ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Bevacizumab; Capecitabine; Chemotherapy; Colorectal cancer; Irinotecan; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE;

EID: 66649083128     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Dušek L, Mužik J, Kubések M et al. Epidemiologie zhoubných nédorů v České republice [online]. Masarykova univerzita 2005, cit. 2009-3-22. Dostupné z http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
2. Hegde SR, Sun W, Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008; 2(1): 135-149.
3. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599. (Pubitemid 27441066)
4. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25(30): 4779-4786. (Pubitemid 350086481)
5. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28(11 Pt 2): 23S-30S.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342. (Pubitemid 38702844)
7. Kocakova I, Spelda S, Kocak I et al. Phase I/II study of capecitabine plus irinotecan (XELIRI) in combination with bevacizumab as first-line therapy in metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting 2006. Proceeding Book, poster No. 13540.